CLINICAL RESEARCH & PRODUCT DEVELOPMENT ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2015
N/A
2016
2017/6
2017
2018/6
2018
2019/6
2019
2020/6
Bankruptcy risk for industry  1.2% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 25.5% 16.1% 14.9% 16.7%  
Credit score (0-100)  0 4 13 15 11  
Credit rating  N/A B BB BB BB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2015
N/A
2016
2017/6
2017
2018/6
2018
2019/6
2019
2020/6

Net sales  0 0 0 0 0  
Gross profit  0.0 -20.0 -1.3 -9.6 -10.2  
EBITDA  0.0 -20.0 -1.3 -9.6 -10.2  
EBIT  0.0 -20.0 -1.3 -9.6 -10.2  
Pre-tax profit (PTP)  0.0 -34.0 -15.1 -23.7 -25.1  
Net earnings  0.0 -34.0 -15.1 -23.7 -25.1  
Pre-tax profit without non-rec. items  0.0 -34.0 -15.1 -23.7 -25.1  

 
See the entire income statement

Balance sheet (kDKK) 
2015
N/A
2016
2017/6
2017
2018/6
2018
2019/6
2019
2020/6

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  0.0 360 344 321 296  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0.0 716 709 700 684  

Net Debt  0.0 -712 -698 -687 -682  
 
See the entire balance sheet

Volume 
2015
N/A
2016
2017/6
2017
2018/6
2018
2019/6
2019
2020/6

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 -20.0 -1.3 -9.6 -10.2  
Gross profit growth  0.0% 0.0% 93.3% -612.1% -6.5%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 716 709 700 684  
Balance sheet change%  0.0% 0.0% -0.9% -1.4% -2.2%  
Added value  0.0 -20.0 -1.3 -9.6 -10.2  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 -1.0 -2.0 -3.0 -4.0  

Profitability 
2015
N/A
2016
2017/6
2017
2018/6
2018
2019/6
2019
2020/6
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 100.0% 100.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% -2.8% -0.2% -1.4% -1.5%  
ROI %  0.0% -5.6% -0.4% -2.9% -3.3%  
ROE %  0.0% -9.4% -4.3% -7.1% -8.2%  

Solidity 
2015
N/A
2016
2017/6
2017
2018/6
2018
2019/6
2019
2020/6
Equity ratio %  0.0% 50.3% 48.5% 45.8% 43.2%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% 3,560.0% 51,795.4% 7,152.9% 6,675.0%  
Gearing %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.0% 0.0%  

Liquidity 
2015
N/A
2016
2017/6
2017
2018/6
2018
2019/6
2019
2020/6
Quick Ratio  0.0 2.0 1.9 1.8 1.8  
Current Ratio  0.0 2.0 1.9 1.8 1.8  
Cash and cash equivalent  0.0 712.0 698.2 686.6 682.4  

Capital use efficiency 
2015
N/A
2016
2017/6
2017
2018/6
2018
2019/6
2019
2020/6
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 328.5 2,030.8 285.2 267.8  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 360.0 344.4 320.7 295.6  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2015
N/A
2016
2017/6
2017
2018/6
2018
2019/6
2019
2020/6
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0